COVID-19 Early Treatment with Non-Steroidal AntiInflammatory Drugs Reduces Hospitalizations and Symptom Duration |Biomedgrid

At the beginning of the SARS-CoV-2 pandemic we stated that, given the new virus and the little-known disease it caused, in the absence of Evidence-Based Medicine indications, patients should have been treated with drugs already available, useful to counteract the pathophysiology of the COVID-19 [1]. Recent literature has confirmed that this could be a successful approach, demonstrating that an early treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), in patients with mild-to-moderate COVID-19, produces significant reduction of hospitalizations and disease duration [2-4]. The NSAIDs have indication in the COVID-19 not only for their antiinflammatory actions but also, some molecules, for their antiviral properties [2,3,5].